1. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017;12:2032-2045.
2. Makino H, Kashihara N, Sugiyama H, Kanao K, Sekikawa T, Okamoto K, et al. Phenotypic modulation of the mesangium reflected by contractile proteins in diabetes. Diabetes. 1996;45:488–495.
3.Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor- A as a key mediator. Diabetes. 1995;44:1139–1146.
4. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315–1321.
5. Guo M, Ricardo SD, Deane JA, Shi M, Cullen-McEwen L, Bertram JF. A stereological study of the renal glomerular vasculature in the db/db mouse model of diabetic nephropathy. J Anat. 2005;207: 813–821.
6. Nyengaard JR, Rasch R. The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia 1993;36;3:189–194.
7. Veron D, Reidy KJ, Bertuccio C, Teichman J, Villegas G, Jimenez, et al. Overexpression of vegf-a in podocytes of adult mice causes glomerular disease. Kidney Int.2010;77:989–999.
8. Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitör. Diabetologia 1999;42:579–588.
9. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999;48:2229–2239.
10. Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding Y, Abe M, et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest. 2004;114:898-907.
11. Nasu T, Maeshima Y, Kinomura M, Hirokoshi-Kawahara K, Tanabe K, Sugiyama H, wt al. Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy. Diabetes 2009;58:2365–2375.
12. Saito D, Maeshima Y, Nasu T, Yamasaki H, Tanabe K, Sugiyama H, et al. Amelioration of renal alterations in obese type 2 diabetic mice by vasohibin-1, a negative feedback regulator of angiogenesis. Am. J. Physiol. Ren. Physiol. 2011;300:873–886.
13. Ren H, Shao Y, Wu C, Lv C, Zhou Y, Wang Q. VASH-1 Regulates Oxidative Stress and Fibrosis in Diabetic Kidney Disease via SIRT1/HIF1α and TGFβ1/Smad3 Signaling Pathways. Front Mol Biosci. 2020 Jul 10;7:137.
14. Mottl AK, Tuttle KR, Bakris GL. Diabetic kidney disease: Manifestations, evaluation, and diagnosis. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on November 27 Dec 2021)
15. McGrath K, Edi R. Diabetic Kidney Disease: Diagnosis, Treatment, and Prevention. Am Fam Physician. 2019 Jun 15;99(12):751-759.
16. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-2045.
17. Fisher H, Hsu C, Vittinghoff E, Lin F, Bansal N. Comparison of Associations of Urine Protein-Creatinine Ratio Versus Albumin-Creatinine Ratio With Complications of CKD: A Cross-sectional Analysis. Am J Kidney Dis. 2013;62(6):10.1053/j.ajkd.2013.07.013.
18. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis 2002;39:1-266.
19. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;5;150:604-612.
20. Osterby R, Nyberg G. New vessel formation in the renal corpuscles in advanced diabetic glomerulopathy. J Diabet Complications. 1987;1:122-127.
21. Kanesaki Y, Suzuki D, Uehara G, Toyoda M, Katoh T, Sakai H, et al. Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis. 2005;45:288-294.
22. Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken RA, Hugo CP. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int. 2005;69:1654-1661.
23. Maeshima Y, Makino H. Angiogenesis and chronic kidney disease. Fibrogenesis Tissue Repair 2010;5;3:13.
24. Hovind P, Tarnow L, Oestergaard PB, Parving HH. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney International. 2000;57:56–61.
25. Kim NH, Oh JH, Seo JA, Lee KW, Kim SG, Choi KM, at al. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney International. 2005;67:167–177.
26. Bates DO, Curry FE. Vascular endothelial growth factor increases microvascular permeability via a Ca2+-dependent pathway. American Journal of Physiology. 1997;273;2:87–694.
27. Barleon B, Sozzani S, Zhou D, Weich HA, MantovaniA, Marm´e D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87;8:3336–3343.
28. Hinamoto N, Maeshima Y, Yamasaki H, Nasu T, Saito D, Watatani H, et al. Exacerbation of diabetic renal alterations in mice lacking vasohibin-1. PLoS One. 2014;25;9:107934.
29. Ren H, Shao Y, Ma X, Yang M, Liu Y, Wang Q. Expression levels of serum vasohibin-1 and other biomarkers in type 2 diabetes mellitus patients with different urinary albumin to creatinine ratios. J Diabetes Complications. 2019;33:477-484.
30. Hinamoto N, Maeshima Y, Saito D, Yamasaki H, Tanabe K, Nasu T, et al. Urinary and Plasma Levels of Vasohibin-1 Can Predict Renal Functional Deterioration in Patients with Renal Disorders. PLoS One. 2014;9:e96932.doi:10.1371 /journal.pone.0096932
31. Tanimura S, Tanabe K, Miyake H, Masuda K, Tsushida K, Morioka T, et al. Renal tubular injury exacerbated by Vasohibin-1 deficiency in a murine cisplatin-induced acute kidney injury model. Am J Physiol Renal Physiol. 2019;15. doi: 10.1152/ajprenal.00045.2019.
32. Hinamoto N, Maeshima Y, Saito D, Yamasaki H, Tanabe K, Nasu T, et al. Renal distribution of Vasohibin-1 in patients with chronic kidney disease. Acta Medica Okayama. 2014;68;4:219–233.